Relation between N-terminal pro-brain natriuretic peptide values and invasively measured left ventricular hemodynamic indices

Experimental and Clinical Cardiology

Volumn 8, Issue 2, 2003, Pages 91-94

  Gremmler, Bernhard ^a   Kunert, Matthias ^a   Schleiting, Heinrich ^a   Kisters, Klaus ^b,c   Ulbricht, Ludger J ^a,d  

^a Marien Hospital Bottrop gGmbH   (Germany)

^b ST ANNA HOSPITAL   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Heart failure; Left heart catheterization; Left ventricular hemodynamics; N terminal pro brain natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMIC PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN DETERMINATION; STATISTICAL ANALYSIS;

EID: 0346895165     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Mukoyahma M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest 1991;87:1402-12.
2. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367-74.
3. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
4. Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996;76:232-7.
5. De Lemos J, Morrow D, Bentley J, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
6. Hama N, Itah H, Shirakami G, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995;92:1558-64.
7. Yu CM, Sanderson JE, Shum IO, et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Eur Heart J 1996;17:1694-702.
8. Valli N, Georges A, Corcuff J-B, et al. Assessment of brain natriuretic peptide in patients with suspected heart failure: Comparison with radionuclide ventriculography data. Clin Chimica Acta 2001;306:19-26.
9. Davidson NC, Naas AA, Hanson JK, et al. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996;77:828-31.
10. Groenning B, Nilsson J, Sondergaard L, et al. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail 2001;3:699-708.
11. Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32.
12. Cowie MR. BNP: Soon to become a routine measure in the care of patients with heart failure? Heart 2000;83:617-8.
13. Remme W, Swedberg K, the Task Force for the Diagnosis and Treatment of Chronic Heart Failure, and the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
14. Francis GS, Benedict C, Johnstone DE, et al., for the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724-9.
15. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet 1993;341:1105-9.
16. Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-I. Eur Heart J 1999;20:1799-807.
17. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J Am Coll Cardiol 2001;37:386-91.
18. Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones on humans. Horm Metab Res 1999;31:487-98.
19. Clerico A, Iervasi G, Del Ry S, et al. Immunoassay methods for the measurement of natriuretic cardiac hormones (ANP, BNP, and related peptides) in humans. J Clin Assay 1999;22:194-204.
20. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1347-51.
21. Cheung BM, Kumana CR. Natriuretic peptides-relevance in cardiovascular disease. JAMA 1998;351:9-13.
22. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: The need for a new generation of immunoassay methods. Clin Chem 2000;46:1529-34.
23. World Medical Organization. Declaration of Helsinki. World Med J 1974;11:281.
24. Yamamoto K, Burnett JCJ, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28:988-94.
25. Hartmann F, Kurowski, Maghsoudi A, et al. Plasma catecholamines and N-terminal proBNP in patients with acute myocardial infarction undergoing primary angioplasty. Z Kardiol 2003;92:73-81.
26. Inoue T, Sakuma M, Yaguchi I, et al. Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction. Am Heart J 2002;143:790-6.
27. Tateishi J, Masutani M, Ohyanagi M, Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 2000;23:776-80.